THMO ThermoGenesis Total Debt to Capital

ThermoGenesis (THMO) is developing a closed digital environment to automate stem cell workflows via PXP platforms and AI analysis. This chart of the market valuation, which accounts for the logistical stability of biobank supplies, records the figure at 7.90. The expansion of ThermoGenesis into the biobanking systems and gene therapy segment provides the company with steady growth momentum within the laboratory equipment sector.

Total debt-to-equity measures the proportion of borrowed funds relative to shareholders' equity, determining the degree of financial leverage and the risks of credit dependency for the business. By analyzing the trend of the total debt-to-equity ratio, an investor assesses the stability of ThermoGenesis (THMO), whose implementation of ESG standards and the greening of diagnostic equipment production require balanced financing to maintain long-term solvency.